The company's purpose is to conduct preclinical and clinical research, discovery and development of new medicines, combinations of medicines, diagnostics and biomarkers for antibody-based therapies and low molecular weight active substances, as well as for cancer diseases, diseases of the immune system and potentially other types of diseases. The company also aims to provide consulting services in the field of research and drug development, including preclinical and clinical research, discovery and development of new medicines, combinations of medicines, diagnostics and biomarkers for new therapies. The company may establish branches and subsidiaries in Switzerland and abroad and participate in other companies in Switzerland and abroad. The company may acquire, hold, manage, encumber, utilize and sell real estate and intellectual property rights in Switzerland and abroad, as well as finance other companies. The company may grant direct or indirect financing to its direct or indirect subsidiaries and third parties, including its direct or indirect shareholders and their direct or indirect subsidiaries, provide securities of all kinds, including by way of pledges or fiduciary transfers or assignments of the company's assets, or guarantees, enter into guarantees or otherwise secure or guarantee the company's or these other companies' obligations, whether for consideration or not. Furthermore, it may engage in liquidity balancing/cash concentration (cash pooling) with the aforementioned companies or join such an arrangement, including periodic account balancing. This also applies without consideration, on preferential terms, without interest, excluding the company's profit motive, and assuming cluster risks. The company may engage in all commercial, financial and other activities that appear to promote the company's purpose or are related to it.
Outbound Leads by COHAGA